Background-In vitro the Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP-1) has been shown to upregulate expression of matrix metalloproteinase 9 (MMP-9), a member of a family of zinc dependent endopeptidases that is believed to facilitate tumour invasion and metastasis by degradation of the extracellular matrix. Aim-To test whether the expression of MMP-9 in Hodgkin's disease correlates with EBV status and survival and to investigate whether LMP-1 expression aVects MMP-9 concentrations in the Hodgkin's disease cell line, L428.
In the Western world, Hodgkin's disease is the most common malignant lymphoma aVecting individuals between the ages of 10 and 30 years. 1 One of its characteristic features is the presence of a small population of large mononucleated or multinucleated Hodgkin and Reed-Sternberg cells surrounded by a much larger mass of non-malignant cell types. 2 The Epstein-Barr virus (EBV), a B cell human herpesvirus that infects most of the world's adult population, is associated with the development of several malignancies, including undiVerentiated nasopharyngeal carcinoma, Burkitt's lymphoma, and post-transplant lymphoproliferative disease in immunosuppressed individuals. More recently, EBV has been linked to the development of Hodgkin's disease. Evidence to support a role for EBV in Hodgkin's disease is provided by the consistently high degree of expression of the EBV transforming protein, latent membrane protein 1 (LMP-1), by Hodgkin and Reed-Sternberg cells in EBV associated patients. Recently, LMP-1 has been shown to upregulate expression of the matrix metalloproteinase 9 (MMP-9) gene in the C33A cell line. 3 MMP-9 is a member of a family of zinc dependent endopeptidases that are believed to facilitate tumour invasion and metastasis through degradation of the extracellular matrix. 4 5 Previous studies suggest that MMP-9 is a key enzyme responsible for the biological aggressiveness of human non-Hodgkin's lymphomas. 6 Raised MMP-9 expression has been reported in several other malignancies including breast, colorectal, and lung cancers. 7 These data suggest that LMP-1 mediated upregulation of MMP-9 might contribute to the progression and spread of EBV associated Hodgkin's disease. Therefore, we wished to determine whether, in Hodgkin's disease, expression of MMP-9 correlated with EBV status and survival. We also examined the influence of LMP-1 expression on the production of MMP-9 in the Hodgkin's disease cell line, L428.
Materials and methods

PATIENT GROUPS
A total of 86 samples of paraYn wax embedded tissue from patients with Hodgkin's disease were examined. A histological diagnosis of Hodgkin's disease was confirmed by review and all cases were subtyped according to the REAL classification system. 8 
IMMUNOHISTOCHEMISTRY
Sections (4 µm thick) were cut from each formalin fixed, paraYn wax embedded tissue sample, adhered to VECTABOND treated slides (Vector Laboratories, Peterborough, UK), and incubated overnight at 37°C. After dewaxing and clearing, endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol, and the sections were transferred to phosphate buVered saline (PBS) at pH 7.6. Sections were preincubated in normal rabbit serum (Dako, Cambridge, UK) for 10 minutes and then incubated at room temperature with a prediluted (1/50) goat polyclonal antibody directed against MMP-9 (C-20; Autogen Bioclear, Calne, Wiltshire, UK), for one hour. Biotinylated rabbit antigoat immunoglobulin was used as the secondary antibody for 30 minutes, followed by streptavidin and biotinylated horseradish peroxidase complex for a further 30 minutes (both Dako). To confirm the specificity of the immunodetection, selected cases were also immunostained with a mouse monoclonal antibody to MMP-9 (clone VIIC2, Lab Vision Corp, Freemont, California, USA) diluted 1/100. Visualisation was carried out using the Sigma FAST TM DAB (3, 3'-diaminobenzidine) peroxidase substrate system (Sigma-Aldrich, Poole, Dorset, UK). Sections were counterstained in haematoxylin and mounted in DPX. One section known to give strong staining was included in each subsequent run as a positive control. Negative controls consisted of the substitution of the MMP-9 primary antibody with appropriate non-immune serum. For the evaluation of immunohistochemical staining, intensity of staining in the malignant cells was graded between + and +++ (where + was weak staining and +++ was the most intense staining).
STATISTICAL ANALYSIS
Kaplan-Meier plots were used to compare the potential diVerences in survival between the three Hodgkin's disease groups with diVering intensities of MMP-9 expression. The MannWhitney test was also used to compare the distribution of MMP-9 categories within EBV negative and EBV positive specimens.
HODGKIN'S DISEASE CELL LINE
Hodgkin's disease cell lines, including KMH2, L591, parental L428, and L428 cells transfected with a cadmium inducible LMP-1 construct (F1L428) were cultured in RPMI-1640 (Gibco-BRL, Paisley, Scotland; UK) supplemented with 5% vol/vol fetal calf serum (FCS; Gibco-BRL), 2 mM L-glutamine, streptomycin (5 mg/100 ml), penicillin (5000 U/100 ml) and amphotericin (250 µg/100 ml) (all Sigma-Aldrich). [9] [10] [11] [12] LMP-1 expression was induced in F1L428 cells by the addition of cadmium chloride (final concentration of 6 µM) to the medium (induction was carried out for six hours). L428 cells that had been transfected with vector DNA only (H2L428) were used as controls. WESTERN BLOTTING For western blot analysis, 10 ml aliquots (approximately 2 × 10 6 cells) of each of the L428 cell lines (H2, F1, and F1 induced) were pelleted by centrifugation at 200 × g for five minutes. The resulting cell pellets were resuspended in 1000 µl of distilled water and sonicated at 4°C for 2.5 minutes (5 × 30 seconds). The protein concentration was determined using the Bio-Rad protein assay (BioRad, Hemel Hempstead, Hertfordshire, UK). Cells were centrifuged and the pellets were resuspended in 200 µl of sodium dodecyl sulphate (SDS) buVer and equal amounts of 1) . In most cases, strong cytoplasmic staining of Hodgkin and ReedSternberg cells was seen. In all cases, several non-malignant cell types were stained, including fibroblasts and macrophages. The specificity of the goat polyclonal antibody for MMP-9 was confirmed by the staining of selected cases with a monoclonal antibody to MMP-9 because both antibodies produced identical staining patterns.
ZYMOGRAPHY
Gelatin zymography of the cell lysates and conditioned media from the parental L428 Hodgkin's disease cell line showed the presence of a band at the molecular weight corresponding to inactive MMP-9. LMP-1 expression was successfully induced in the F1L428 line as demonstrated by western blotting using the CS1-4 reagent (fig 2A and B) . However, when conditioned media or cell pellets from this cell line were subjected to zymography, MMP-9 values were identical to those seen in the parental L428 cells (fig 2C) . MMP-9 was also detected by zymography in the KMH2 Hodgkin's disease cell line, whereas low or undetectable amounts of MMP-9 were found in the L591 Hodgkin's disease cell line. None of the samples contained detectable amounts of activated MMP-9.
STATISTICAL ANALYSIS
The intensity of MMP-9 immunostaining of individual Hodgkin's disease cases was variable and there was no correlation between the degree of MMP-9 expression and EBV status. In addition, MMP-9 expression was independent of histological subtype. For the MannWhitney test, in which the distribution of MMP-9 categories is compared between EBV negative and EBV positive status, the Z statistic was −0.16, and the p value was 0.88. The Kaplan-Meier plots (fig 3) showed that there were no significant diVerences between the degree of MMP-9 expression and patient outcome. However, there were too few patients in the MMP-9 positive category for a meaningful analysis of this group.
Discussion
Although several MMPs have been implicated in the spread of tumours, MMP-9 may be particu- larly relevant to the progression of lymphomas. MMP-9 has been shown to be important for the in vitro degradation of extracellular matrix components by non-Hodgkin's lymphoma cells. 6 In vivo, MMP-9 is also overexpressed in a subset of high grade non-Hodgkin's lymphomas, and this correlates with a poor clinical outcome. [13] [14] [15] Previous studies have shown that MMP-9 expression is increased in EBV latency type III B cell lymphoma cell lines compared with type I cells, where there is a restricted expression of virus genes. 3 Furthermore, expression of MMP-9 in the C33A cell line was increased by transfection of the EBV encoded LMP-1. 3 LMP-1 is transforming in Rat-1 cells and induces many of the phenotypic changes seen in EBV infected B cells, including expression of the B cell activation markers, CD23 and CD40; upregulation of cell adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), lymphocyte function associated antigen 1 (LFA-1), and LFA-3; and cytokine production. [16] [17] [18] LMP-1 also protects B cells from cell death by the upregulation of several anti-apoptosis genes including Bcl-2, Mcl-1, and A20. [19] [20] [21] [22] Many of the phenotypic and growth transforming eVects of LMP-1 are the result of the activation of a variety of signalling pathways, many of which converge on the NF-B (nuclear factor B) and AP-1 transcription factors. 23 24 Given that LMP-1 is highly expressed in a proportion of Hodgkin's disease tumours, 25 26 and also the potential importance of MMP-9 in the progression of lymphomas, we examined the expression of MMP-9 in a series of Hodgkin's disease tumours.
The results of our study show that MMP-9 is consistently expressed by the malignant Hodgkin and Reed-Sternberg cells of Hodgkin's disease. Furthermore, studies on the Hodgkin's disease cell lines showed that L428 and KMH2 cells secreted MMP-9. Although the intensity of MMP-9 immunostaining within individual Hodgkin's disease tumours varied, there was no correlation between the degree of MMP-9 expression and EBV status. This was confirmed by the induction of LMP-1 expression in L428 cells, which resulted in no detectable increase in MMP-9 values.
A recent study has shown that upregulation of MMP-9 by LMP-1 is dependent upon the two activating regions of LMP-1 (known as C terminus activating regions, CTAR-1 and CTAR-2) and that the NF-B and AP-1 sites in the MMP-9 promoter are also required. 27 Constitutive activation of NF-B (p50/p65) has been described as a common feature of Hodgkin and Reed-Sternberg cells. 28 29 Thus, it may be that NF-B mediated upregulation of MMP-9 is likely in Hodgkin and Reed-Sternberg cells even in the absence of LMP-1.
Although the exact role of MMP-9 expression in the spread of Hodgkin's disease tumours has yet to be established, its consistent expression suggests the potential for therapeutic interventions using MMP-9 inhibitors.
